$21.53
+0.16 (+0.73%)
Open$21.91
Previous Close$21.37
Day High$21.91
Day Low$20.78
52W High$40.65
52W Low$13.35
Volume—
Avg Volume660.2K
Market Cap1.45B
P/E Ratio—
EPS$-2.39
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
-12.9% upside
Current
$21.53
$21.53
Target
$18.74
$18.74
$15.89
$18.74 avg
$31.24
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 572.13M | 572.72M | 559.98M |
| Net Income | -99,921,707 | -80,567,499 | -92,627,690 |
| Profit Margin | -17.5% | -14.1% | -16.5% |
| EBITDA | -119,066,634 | -104,548,216 | -110,415,827 |
| Free Cash Flow | -98,412,160 | -88,741,836 | -111,480,768 |
| Rev Growth | +16.0% | -4.7% | +5.4% |
| Debt/Equity | 0.49 | 0.55 | 0.51 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.34 | +1.08% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $461.10 | +0.18% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $168.18 | +0.36% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $546.92 | +0.81% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $908.12 | +0.58% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $157.53 | +0.56% | 28.8 | 23.28B |